FDA Accepts Application for Bepirovirsen#
The U.S. Food and Drug Administration (FDA) has accepted the New Drug Application for bepirovirsen, a new treatment aimed at adults with chronic hepatitis B. This investigational drug, developed by Ionis Pharmaceuticals, is currently under Priority Review, which means the FDA will expedite its evaluation process.
Breakthrough Therapy Designation#
Bepirovirsen has been granted Breakthrough Therapy designation by the FDA, highlighting its potential benefits over existing treatments. The FDA has set a target action date of October 26, 2026, for its decision. Previously, the drug received Fast Track designation in February 2024, which also aims to speed up its development and review.
Clinical Trial Results#
The application for bepirovirsen was supported by results from Phase 3 clinical trials known as B-Well 1 and B-Well 2. These trials showed that bepirovirsen, when used alongside standard treatment, resulted in higher functional cure rates compared to standard treatment alone. A functional cure means the hepatitis B virus is undetectable in the blood for at least 24 weeks after stopping treatment. Results from these trials will be presented at an upcoming liver health congress in May.
Financial Overview of Ionis Pharmaceuticals#
Chronic hepatitis B is a significant global health issue, affecting over 250 million people worldwide, including 1.7 million in the U.S. Current treatments often require lifelong therapy with low cure rates. Despite the promising developments with bepirovirsen, Ionis Pharmaceuticals faces financial challenges, reporting a revenue of $943.71 million in the past year but with a low gross profit margin of 1.29%. Analysts do not expect the company to turn a profit this year, although it maintains a strong balance sheet with sufficient liquid assets.
Bepirovirsen works by targeting the genetic components of the hepatitis B virus, aiming to reduce virus levels and enhance the immune response. It has shown a safety profile consistent with earlier studies.
GSK licensed bepirovirsen from Ionis in 2019, and under this agreement, Ionis is set to receive various payments and royalties based on the drug's sales.